Some are saying do not unblind and talking about their experience bringing products to market. I would think that their experience also told them that if the playing field changed then they needed to reassess their tactics. I see the FDA now proven willingness to approve big pharma drugs of doubtful benefit changes the playing field. I see AZar’s interview alluding to more such approvals as changing the playing field. I see Dr NPs previous statements that Britain and the Philippines among others wanted to see data as confirmation that a change in Cydy tactics would have merit. I have run large operations in life or death situations. You must be willing to adapt your tactics to changing opportunities and necessities. I have come to the conclusion that a change is merited and if the MHRA and Philippines discussions don’t bear immediate fruit then unblind the data!